Last €14.06 EUR
Change Today +0.185 / 1.33%
Volume 0.0
I76 On Other Exchanges
As of 2:18 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

ironwood pharmaceuticals inc (I76) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/28/15 - €14.99
52 Week Low
04/15/14 - €6.89
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ironwood pharmaceuticals inc (I76) Related Businessweek News

No Related Businessweek News Found

ironwood pharmaceuticals inc (I76) Details

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company’s lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

464 Employees
Last Reported Date: 02/18/15
Founded in 1998

ironwood pharmaceuticals inc (I76) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $100.0K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $376.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $366.6K
Compensation as of Fiscal Year 2013.

ironwood pharmaceuticals inc (I76) Key Developments

Ironwood Pharmaceuticals Reports Unaudited Consolidated Earnings Results for the Fourth Quarter Year Ended December 31, 2014

Ironwood Pharmaceuticals reported unaudited consolidated earnings results for the fourth quarter year ended December 31, 2014. The company reported a narrower loss for the recent quarter on revenue that was more than 600% higher than the same quarter of 2013. The company reported a net loss of $37.6 million, or $0.27 per basic and diluted share. For the same quarter last year, IRWD reported a loss of $52.0 million, or $0.43 per basic and diluted share. Revenue totaled $38.1 million, beating the estimated $35.2 million, and significantly higher than fourth quarter 2013 total revenue of $5.0 million largely due to $33.7 million in profits from LINZESS realized in the fourth quarter of 2014. Loss from operations was $33,125,000 compared to $46,738,000 a year ago. For the year, the company's collaborative arrangements revenue was $76,436,000 compared to $22,881,000 a year ago. Loss from operations was $169,370,000 compared to $252,002,000 a year ago. Net loss was $189,618,000 or $1.39 per basic and diluted share compared to $272,812,000 or $2.35 per basic and diluted share a year ago.

Ironwood Pharmaceuticals, Inc. Reports Positive Top-Line Data from Exploratory Phase IIa Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals, Inc. announced that top-line data from an exploratory Phase IIa clinical study indicate IW-3718 improved heartburn and certain other symptoms associated with refractory gastroesophageal reflux disease (GERD). Based on these initial data, Ironwood intends to advance IW-3718 into a dose-ranging Phase IIb study. Refractory GERD, which affects an estimated 8 million Americans, is characterized by the chronic presence of symptoms such as heartburn despite treatment with a proton pump inhibitor (PPI) to suppress stomach acid. Research suggests some refractory GERD patients may experience reflux of bile from the intestine into the stomach and esophagus. IW-3718 is a novel formulation of a bile acid sequestrant designed to bind over an extended period of time to bile that refluxes into the stomach and upper small intestine, potentially providing symptomatic relief in refractory GERD. Heartburn was the most severe and most frequent symptom experienced by patients before starting study treatment. Average baseline heartburn severity among study participants was 3.5 on a 10-point scale, with 0 representing no heartburn and 10 representing very severe heartburn. The improvement in heartburn severity for IW-3718-treated patients was 1.7 points in the overall trial population and 2.1 points in the subgroup of patients who tested positive for bile reflux (versus 1.2 points and 1.1 points, respectively, for the placebo-treated groups in each comparison). In terms of frequency, patients entering the trial reported that only 13.7% of their days were free of heartburn. The percentage of heartburn-free days for IW-3718-treated patients increased by 30.3% in the overall trial population and 34.6% in the bile reflux-positive subgroup (versus 24.7% and 23.6%, respectively, for the placebo-treated groups in each analysis). Patients receiving IW-3718 also demonstrated encouraging improvements in regurgitation and in some upper GI symptoms that are often associated with GERD, including epigastric burning, early fullness and post-prandial fullness. Symptom improvements were in the bile reflux-positive subgroup. Additionally, 45.7% and 56.3% of IW-3718-treated patients in the overall trial population and in the bile reflux-positive subgroup, respectively, were responders regarding degree of relief of overall GERD symptoms (versus 27.7% and 29.4%, respectively, for the placebo-treated groups in each analysis). Certain upper GI symptoms that did not appear to be impacted by treatment included nausea, epigastric pain and bloating. IW-3718 was generally well-tolerated with the most common adverse event being constipation. The randomized, double-blind, placebo-controlled, multi-site, Phase IIa study enrolled 93 patients with a confirmed diagnosis of GERD who were taking a PPI and continuing to experience frequent GERD symptoms, including heartburn at least four days per week. The trial included a two-week pretreatment period during which baseline symptoms were assessed via an electronic diary, followed by a randomization period in which patients had the option to undergo 24-hour Bilitec® and pH monitoring to assess the extent of esophageal exposure to bile and acid reflux. Patients were randomized to receive either 1,000 mg of IW-3718 or placebo twice-daily for four weeks. Patients continued to take their PPI during the pretreatment, randomization and treatment periods. The exploratory study evaluated a number of GERD-related symptoms rather than specifying a primary endpoint, and as such was not powered to establish the statistical significance of a particular endpoint. Data presented for heartburn severity and heartburn-free days reflect change from baseline to week four. For the responder analysis, responders regarding degree of relief of overall GERD symptoms were defined as patients who reported scores of 1 (completely relieved) or 2 (considerably relieved) on a seven-point scale for at least two out of four weeks in the treatment period, or who reported scores of 1, 2 or 3 (somewhat relieved) for all four weeks.

Ironwood Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 12, 2015

Ironwood Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I76:GR €14.06 EUR +0.185

I76 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $6.13 USD +0.24
Nektar Therapeutics $13.07 USD +0.09
Progenics Pharmaceuticals Inc $6.51 USD -0.12
Sucampo Pharmaceuticals Inc $15.38 USD -0.62
Theravance Inc $18.06 USD -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation I76 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.3x
Price/Book 24.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at